Hypothyroidism Treatment

Provides thryoid replacement therapy in all conditions of inadequate production of thyroid hormones (hypothyroidism) in dogs. Active Ingredients: Each SOLOXINE (levothyroxine sodium, U.S.P.) tablet provides synthetic crystalline levothyroxine sodium (L-thyroxine). Dosage forms available: 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, and 0.8 mg tablets. Indications: Provides thyroid replacement therapy in all conditions of inadequate production of thyroid hormones. Hypothyroidism is the generalized metabolic disease resulting from deficiency of the thyroid hormones levothyroxine (T4) and liothyronine (T3). SOLOXINE (levothyroxine sodium) will provide levothyroxine (T4) as a substrate for the physiologic deiodination to liothyronine (T3). Administration of levothyroxine sodium alone will result in complete physiologic thyroid replacement. Pharmacology: Levothyroxine sodium acts, as does endogenous thyroxine, to stimulate metabolism, growth, development and differentiation of tissues. It increases the rate of energy exchange and increases the maturation rate of the epiphyses. Levothyroxine sodium is absorbed rapidly from the gastro-intestinal tract after oral administration. Following absorption, the compound becomes bound to the serum globulin fraction. For purposes of comparison, 0.1 mg of levothyroxine sodium elicits a clinical response approximately equal to that produced by one grain (65 mg) of desiccated thyroid. Dosage and Administration: The initial recommended daily dose is 0.1 mg/10 lbs. (4.5 kg) of body weight. The dosage may then be adjusted according to the patient’s response by monitoring T4 blood levels at time intervals of four (4) weeks. SOLOXINE tablets may be administered orally or placed in the food. Contraindications: Levothyroxine sodium therapy is contraindicated in thyrotoxicosis, acute myocardial infarction and uncorrected adrenal insufficiency. Use in pregnant females has not been evaluated. Precautions: Store at a controlled

powered by Yahoo shopping